MedTrace Logo

High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures

NCT01744613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-01-14

No results posted yet for this study

Summary

Antiplatelet therapy with clopidogrel is recommended following peripheral endovascular procedures. The clinical significance of an inadequate response to clopidogrel following percutaneous coronary interventions has been recently recognized.This study was designed to investigate platelet responsiveness to Clopidogrel following endovascular therapy of peripheral arterial disease using the VerifyNow P2Y12 point-of-care testing and to determine the optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition influencing outcomes of infrainguinal angioplasty or stenting in patients receiving clopidogrel antiplatelet therapy.

Conditions

  • Influence of PRU Values on Primary Outcome

Sponsors & Collaborators

  • University of Patras

    lead OTHER

Principal Investigators

  • Dimitrios Siablis, MD, PhD · University Hospital of Patras

  • Dimitrios Karnabatidis, MD, PhD · University Hospital of Patras

  • Stavros Spiliopoulos, MD, PhD · University Hospital of Patras

  • Georgios Pastromas, MD · University Hospital of Patras

  • Konstantinos Katsanos, MD, PhD · University Hospital of Patras

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01744613 on ClinicalTrials.gov